<?xml version='1.0' encoding='utf-8'?>
<document id="22426195"><sentence text="Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles."><entity charOffset="26-35" id="DDI-PubMed.22426195.s1.e0" text="docetaxel" /><entity charOffset="40-52" id="DDI-PubMed.22426195.s1.e1" text="ketoconazole" /><entity charOffset="60-66" id="DDI-PubMed.22426195.s1.e2" text="folate" /><pair ddi="false" e1="DDI-PubMed.22426195.s1.e0" e2="DDI-PubMed.22426195.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22426195.s1.e0" e2="DDI-PubMed.22426195.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22426195.s1.e0" e2="DDI-PubMed.22426195.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22426195.s1.e1" e2="DDI-PubMed.22426195.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22426195.s1.e1" e2="DDI-PubMed.22426195.s1.e2" /></sentence><sentence text="Docetaxel is used in the treatment of many types of cancer, but its entry into the brain is restricted by p-glycoprotein (p-gp) efflux"><entity charOffset="0-9" id="DDI-PubMed.22426195.s2.e0" text="Docetaxel" /></sentence><sentence text=" A potential drug-drug interaction exists between docetaxel and ketoconazole because both agents are metabolized hepatically by the cytochrome P-450 system, and ketoconazole can inhibit p-gp efflux of docetaxel at blood brain barrier"><entity charOffset="50-59" id="DDI-PubMed.22426195.s3.e0" text="docetaxel" /><entity charOffset="64-76" id="DDI-PubMed.22426195.s3.e1" text="ketoconazole" /><entity charOffset="161-173" id="DDI-PubMed.22426195.s3.e2" text="ketoconazole" /><entity charOffset="201-210" id="DDI-PubMed.22426195.s3.e3" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.22426195.s3.e0" e2="DDI-PubMed.22426195.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22426195.s3.e0" e2="DDI-PubMed.22426195.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22426195.s3.e0" e2="DDI-PubMed.22426195.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22426195.s3.e0" e2="DDI-PubMed.22426195.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22426195.s3.e1" e2="DDI-PubMed.22426195.s3.e1" /><pair ddi="false" e1="DDI-PubMed.22426195.s3.e1" e2="DDI-PubMed.22426195.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22426195.s3.e1" e2="DDI-PubMed.22426195.s3.e3" /><pair ddi="false" e1="DDI-PubMed.22426195.s3.e2" e2="DDI-PubMed.22426195.s3.e2" /><pair ddi="false" e1="DDI-PubMed.22426195.s3.e2" e2="DDI-PubMed.22426195.s3.e3" /></sentence><sentence text=" Hence, these two drugs were loaded in solid lipid nanoparticles (SLNPs) and surface of these NPs were modified with folic acid for brain targeting"><entity charOffset="117-127" id="DDI-PubMed.22426195.s4.e0" text="folic acid" /></sentence><sentence text=" These NPs were characterized for particle size, zeta potential, entrapment efficiency, in vitro drug release, cytotoxicity, and cell uptake in brain endothelial cell lines" /><sentence text=" Plasma and brain pharmacokinetics have shown increased brain uptake of docetaxel with surface-modified dual drug-loaded SLNPs"><entity charOffset="72-81" id="DDI-PubMed.22426195.s6.e0" text="docetaxel" /></sentence><sentence text=" Brain permeation coefficient (K(in)) of folate-grafted docetaxel and ketoconazole loaded SLNPs was 44 times higher than that of Taxotere"><entity charOffset="41-47" id="DDI-PubMed.22426195.s7.e0" text="folate" /><entity charOffset="56-65" id="DDI-PubMed.22426195.s7.e1" text="docetaxel" /><entity charOffset="70-82" id="DDI-PubMed.22426195.s7.e2" text="ketoconazole" /><entity charOffset="129-137" id="DDI-PubMed.22426195.s7.e3" text="Taxotere" /><pair ddi="false" e1="DDI-PubMed.22426195.s7.e0" e2="DDI-PubMed.22426195.s7.e0" /><pair ddi="false" e1="DDI-PubMed.22426195.s7.e0" e2="DDI-PubMed.22426195.s7.e1" /><pair ddi="false" e1="DDI-PubMed.22426195.s7.e0" e2="DDI-PubMed.22426195.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22426195.s7.e0" e2="DDI-PubMed.22426195.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22426195.s7.e1" e2="DDI-PubMed.22426195.s7.e1" /><pair ddi="false" e1="DDI-PubMed.22426195.s7.e1" e2="DDI-PubMed.22426195.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22426195.s7.e1" e2="DDI-PubMed.22426195.s7.e3" /><pair ddi="false" e1="DDI-PubMed.22426195.s7.e2" e2="DDI-PubMed.22426195.s7.e2" /><pair ddi="false" e1="DDI-PubMed.22426195.s7.e2" e2="DDI-PubMed.22426195.s7.e3" /></sentence><sentence text=" Hence, these NPs were suitable for the delivery of lipophilic anticancer drugs to the brain" /><sentence text="" /><sentence text="In this paper, successful delivery of docetaxel and ketoconazole is reported using solid lipid nanoparticles surface modified with folic acid for brain targeting, which may pave the way to optimized clinical applications of lipophilic anticancer drugs to the brain"><entity charOffset="38-47" id="DDI-PubMed.22426195.s10.e0" text="docetaxel" /><entity charOffset="52-64" id="DDI-PubMed.22426195.s10.e1" text="ketoconazole" /><entity charOffset="131-141" id="DDI-PubMed.22426195.s10.e2" text="folic acid" /><pair ddi="false" e1="DDI-PubMed.22426195.s10.e0" e2="DDI-PubMed.22426195.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22426195.s10.e0" e2="DDI-PubMed.22426195.s10.e1" /><pair ddi="false" e1="DDI-PubMed.22426195.s10.e0" e2="DDI-PubMed.22426195.s10.e2" /><pair ddi="false" e1="DDI-PubMed.22426195.s10.e1" e2="DDI-PubMed.22426195.s10.e1" /><pair ddi="false" e1="DDI-PubMed.22426195.s10.e1" e2="DDI-PubMed.22426195.s10.e2" /></sentence><sentence text="" /></document>